The current BAY 94-9343 program is directed against the target molecule mesothelin.
BAY 94-9343, a HuCAL-derived antibody-drug conjugate, showed potent, targeted anticancer activity against mesothelin- expressing tumors in preclinical testing.
The current BAY 94-9343 program is directed against the target molecule mesothelin.
BAY 94-9343, a HuCAL-derived antibody-drug conjugate, showed potent, targeted anticancer activity against mesothelin- expressing tumors in preclinical testing.